The company's principal activity is to research and development of new pharmaceutical products for the treatment of human diseases. The company is currently focusing of commercialization of thymosin beta4, a 43 amino acid peptide. This product is used for the treatment of injured tissues and non healing wounds to enable more rapid repair and tissue generation. The company's new pharmaceutical products are used for the treatment of diseases or conditions that arise as a result of immune system disorders, including chronic viral infections, cancer and auto immune disease.
